Skip to main content

Juul products on display at a store in New York, on Aug. 1, 2019.

Brittainy Newman/The New York Times News Service

Altria Inc. took a US$4.5-billion hit from its investment in beleaguered electronic-cigarette maker Juul Labs Inc. on Thursday, the latest setback for the startup as a regulatory crackdown on vaping threatens to upend the fast-growing industry.

The writedown highlights the spectacular reversal in Juul’s fortunes in the past few months, with its valuation shrinking by more than a third to roughly US$24-billion since Altria bought a 35-per-cent stake in December.

With the deal, the U.S. maker of Marlboro had hoped to tap the market for vaping in the face of declining smoking rates and cigarette sales in the United States.

Story continues below advertisement

But increased political backlash and regulatory bans after a surge in teenage vaping have clouded Juul’s future and were largely responsible for the collapse of Altria’s merger talks with Philip Morris International Inc. last month.

Juul appointed a long-time Altria executive as its chief executive officer last month in a bid to rebuild its image. The company has also cut jobs, suspended advertising in the United States and revamped its management.

“While we had a range of scenarios when we made the investment, we did not anticipate this dramatic a change in the e-vapour category,” Altria CEO Howard Willard said on a conference call with analysts.

Mr. Willard said growth in e-cigarette volumes is likely to slow down in the United States compared with the company’s original estimates.

Altria is not the only company taking a hit from the slump in Juul’s valuation. Fidelity Investments’ US$26.7-billion Blue Chip Growth Fund recently cut the value of its stake in the vaping company by nearly half.

U.S. health regulators have announced plans to pull flavoured e-cigarette products from the market, and several states and cities, including Juul’s home territory San Francisco, have moved to ban them.

Antitrust enforcers are also probing Altria for potentially exerting influence over Juul in the resignation of former CEO Kevin Burns, who oversaw the San Francisco-based company’s meteoric growth from a 300-person startup to an international operation employing thousands.

Story continues below advertisement

Altria on Thursday cited a number of reasons for the writedown, including higher chances of the U.S. Food and Drug Administration removing flavoured e-vapour products from the market as well as bans in the United States.

While vaping devices, which vapourize a liquid containing nicotine, have borne the brunt of the regulatory crackdown globally, the U.S. Food and Drug Administration has authorized tobacco heating product iQOS, a rival non-smoking technology.

Altria holds the rights to sell iQOS in the United States.

“We believe that, with current adult smoker trends and e-vapor disruption, it’s an opportune time to expand the availability of these options,” Mr. Willard said in its earnings statement.

The company swung to a net loss of US$2.60-billion in the third quarter due to the charge, and cut its profit growth forecast for the next three years.

Altria’s shares were down 0.5 per cent at US$45.74.

Story continues below advertisement

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter